Medallion Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

Medallion Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$168	Buy	+3	New	+$156	﹤0.01%	1091

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Medallion Wealth Advisors's RPRX Position: Q2 2026 in Review

Medallion Wealth Advisors opened a new position in Royalty Pharma (RPRX) in Q2 2026: 3 shares worth $168. The stake represents ﹤0.01% of the portfolio and ranks #1091 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Medallion Wealth Advisors held 3 shares of Royalty Pharma worth $168 as of Q2 2026.
Royalty Pharma was a new Medallion Wealth Advisors position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #1091 holding.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.